CN110590949A - Method for preparing myoglobin pairing monoclonal antibody and pairing monoclonal antibody prepared by method - Google Patents

Method for preparing myoglobin pairing monoclonal antibody and pairing monoclonal antibody prepared by method Download PDF

Info

Publication number
CN110590949A
CN110590949A CN201910881837.4A CN201910881837A CN110590949A CN 110590949 A CN110590949 A CN 110590949A CN 201910881837 A CN201910881837 A CN 201910881837A CN 110590949 A CN110590949 A CN 110590949A
Authority
CN
China
Prior art keywords
monoclonal antibody
plate
pbst
myo
myoglobin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910881837.4A
Other languages
Chinese (zh)
Inventor
熊宁
张晓杰
李光
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Apis Biotechnology Co ltd
Original Assignee
Beijing Apis Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Apis Biotechnology Co ltd filed Critical Beijing Apis Biotechnology Co ltd
Priority to CN201910881837.4A priority Critical patent/CN110590949A/en
Publication of CN110590949A publication Critical patent/CN110590949A/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/02—Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/795—Porphyrin- or corrin-ring-containing peptides
    • G01N2333/805—Haemoglobins; Myoglobins

Abstract

The invention discloses a method for preparing a myoglobin pairing monoclonal antibody and the pairing monoclonal antibody prepared by the method. The method comprises the steps of preparing hybridoma cells secreting the anti-myoglobin monoclonal antibody and screening paired monoclonal antibodies. The invention adopts sheep anti-MYO purified IgG to pre-coat the ELISA plate, and then MYO antigen is added to indirectly coat the MYO antigen. Compared with direct coating of MYO antigen, the site exposed by indirect coating of MYO antigen is changed, the previous epitope preference is broken through, monoclonal antibody aiming at new MYO antigen epitope is screened, and thus the screening probability of MYO paired monoclonal antibody is improved.

Description

Method for preparing myoglobin pairing monoclonal antibody and pairing monoclonal antibody prepared by method
Technical Field
The invention relates to a preparation method of a monoclonal antibody, in particular to a method for preparing a myoglobin pairing monoclonal antibody, and also relates to the pairing monoclonal antibody prepared by the method. The invention belongs to the field of biotechnology.
Background
Myoglobin (Myoglobin, MYO) is a heme protein consisting of a polypeptide chain of 153 amino acids and an iron-containing heme prosthetic group, is present in tissues such as skeletal muscle and cardiac muscle of mammals, and is mainly used for storing and distributing oxygen. Because Mb has a small molecular weight, can be quickly released from damaged cells, the blood concentration of Mb rapidly rises within 1-3 hours after AMI (acute myocardial infarction) disease occurs, the peak value is reached within 6-7 hours, and nearly all MYO of patients suffering from Acute Myocardial Infarction (AMI) rises within l2 hours, and the rise range is larger than that of each myocardial enzyme, so that the Mb can be used as an early diagnosis marker of AMI, and the myocardial infarction area and thrombolytic curative effect can be estimated according to the marker.
At present, the domestic MYO detection methods include Radioimmunoassay (RIA), ELISA, fluorescence immunoassay and the like. The ELISA has the advantages of high sensitivity, strong specificity, accurate quantification, simple operation, suitability for simultaneous detection of multiple specimens, no need of special equipment and instruments and the like, and has wide application prospect. High-quality MYO monoclonal antibody (mAb) has been prepared abroad, and a MYO double-antibody sandwich ELISA kit is successfully developed, but the kit is expensive and has higher detection cost. The principle of ELISA double antibody sandwich method (enzyme linked immunosorbent assay-sandwich technique) is that specific antibody is combined on solid phase carrier to form solid phase antibody, then combined with corresponding antigen in serum to be detected to form immune complex, after washing, enzyme labeled antibody is added to combine with antigen in immune complex to form enzyme labeled antibody-antigen-solid phase antibody complex, substrate is added for color development to judge antigen content, and in the process of double antibody sandwich matching, only 2 monoclonal antibodies which aim at different epitopes and have far space positions are possible to form matching. Therefore, the key point of preparing the MYO double-antibody sandwich ELISA kit lies in obtaining high-quality paired monoclonal antibodies, but the preparation difficulty of the myoglobin paired monoclonal antibodies is high, and the main reason is that when the myoglobin is coated by a conventional method, the dominant sites exposed on an enzyme label plate by the antigen are excessively concentrated, so that the identification sites of the screened monoclonal antibodies are also concentrated on a few MYO sites, and the screened monoclonal antibodies have strong preference, and therefore, paired monoclonal antibody cell strains are difficult to screen.
In order to screen more MYO paired monoclonal antibodies, the invention adopts sheep anti-MYO purified IgG to pre-coat an enzyme label plate, and then MYO antigen is added to indirectly coat the MYO antigen. Compared with direct coating of MYO antigen, the site exposed by indirect coating of MYO antigen is changed, the previous epitope preference is broken through, monoclonal antibody aiming at new MYO antigen epitope is screened, and thus the screening probability of MYO paired monoclonal antibody is improved.
Disclosure of Invention
The invention aims to provide a novel method for preparing a myoglobin pairing monoclonal antibody, which can overcome the defects of concentrated recognition sites, strong preference and the like of the monoclonal antibody screened by the existing method.
In order to achieve the purpose, the invention adopts the following technical means:
the invention relates to a method for preparing a myoglobin pairing monoclonal antibody, which comprises the steps of preparing hybridoma cells secreting an anti-myoglobin monoclonal antibody and screening the pairing monoclonal antibody; when the hybridoma secreting the anti-myoglobin monoclonal antibody is screened by using an indirect ELISA method, a goat anti-MYO purified IgG coats an enzyme label plate, then a MYO antigen is added, then hybridoma cell culture supernatant and goat anti-mouse IgG-HRP are sequentially added, a color development reading plate is performed to obtain the hybridoma secreting the anti-myoglobin monoclonal antibody, and then monoclonal antibodies capable of being paired are screened from the hybridoma.
In the method of the present invention, preferably, the hybridoma secreting an anti-myoglobin monoclonal antibody is prepared by the following steps:
1) cell fusion: separating spleen of mouse with immune myoglobin antigen, preparing B cell suspension, mixing with SP2/0 cell, centrifuging, and performing cell fusion culture;
2) enzyme label plate coating: na for goat anti-MYO purified IgG2CO3-NaHCO3Diluting the buffer solution, adding the diluted buffer solution into an enzyme label plate, coating the enzyme label plate at 2-8 ℃ overnight, and washing the plate for 1 time by PBST;
3) adding MYO antigen: adding MYO antigen into the ELISA plate after PBST, incubating at 37 ℃, and washing the plate for 1 time by PBST;
4) adding hybridoma cell culture supernatant: aseptically sampling the fusion cell culture supernatant, adding the fusion cell culture supernatant into an enzyme label plate, incubating at 37 ℃, and washing the plate for 1 time by PBST;
5) addition of goat anti-mouse IgG-HRP: diluting goat anti-mouse IgG-HRP to working concentration with PBST, incubating at 37 ℃, and washing the plate for 2 times with PBST;
6) developing and reading the plate: addition of H2O2Developing the substrate with-TMB at 37 ℃ in the absence of light, adding 2M H2SO4And (3) stopping color development, placing the mixture in an enzyme labeling instrument, and reading a plate at 450nm/630nm double-wavelength to obtain the hybridoma secreting the anti-myoglobin monoclonal antibody.
Among them, preferably, spleen of a mouse immunized with myoglobin antigen is isolated, B cell suspension is prepared, mixed with SP2/0 cells and centrifuged, cell fusion is performed with PEG1450, culture is performed with DMEM medium containing 2% v/v HAT and 10% v/v fetal bovine serum, the medium is changed on day 4 after fusion, the original medium is gently aspirated, and culture is performed with DMEM medium containing 1% v/v HT and 10% v/v fetal bovine serum.
Wherein, preferably, the goat anti-MYO purified IgG in step 2) is treated with 50mM Na2CO3-NaHCO3Diluting buffer solution (pH9.6) to 5ug/ml, 100 ul/well, coating overnight at 2-8 deg.C, and washing plate with PBST for 1 time; in step 3), the MYO antigen is diluted to 1ug/ml and 100 ul/well by PBST, incubated at 37 ℃ for 30min, and washed by PBST for 1 time.
Among them, preferably, in step 5), the goat anti-mouse IgG-HRP was diluted with PBST to a working concentration of 100 ul/well, incubated at 37 ℃ for 30min, and washed 2 times with PBST.
In the method of the present invention, preferably, the screening of the matsumab is performed according to the following steps:
1) coating with purified monoclonal antibody: purifying an ascites monoclonal antibody of a hybridoma cell secreting the anti-myoglobin monoclonal antibody, diluting the purified monoclonal antibody, adding the diluted purified monoclonal antibody into a new enzyme label plate, coating overnight, and washing the plate for 1 time by PBST;
2) loading MYO antigen: adding MYO antigen into the ELISA plate after PBST, incubating at 37 ℃, and washing the plate for 1 time by PBST;
3) loading HRP enzyme-labeled monoclonal antibody: diluting the HRP enzyme-labeled monoclonal antibody matched with the coated monoclonal antibody by PBST, adding the diluted HRP enzyme-labeled monoclonal antibody into an enzyme-labeled plate, incubating at 37 ℃, and washing the plate for 2 times by PBST;
4) developing and reading the plate: addition of H2O2Developing the substrate with-TMB at 37 ℃ in the absence of light, adding 2M H2SO4And (3) stopping color development, placing the sample in an enzyme-labeling instrument, reading a plate with 450nm/630nm double-wavelength, and determining that the sample can be matched if the wavelength of 450nm/630nm is more than or equal to 1.0.
Wherein, preferably, 50mM Na is used for purifying the monoclonal antibody in the step 1)2CO3-NaHCO3Buffer (pH9.6) diluted to 5ug/ml, 100 ul/hole, 2-8 ℃ overnight coating, PBST washing plate 1 times.
Wherein, preferably, the MYO antigen in the step 2) is diluted to 1ug/ml and 100 ul/well by PBST, incubated for 30min at 37 ℃, and washed by PBST for 1 time; in the step 3), the HRP enzyme-labeled monoclonal antibody matched with the coated monoclonal antibody is diluted to the working concentration by PBST, 100 ul/hole is incubated for 30min at 37 ℃, and the PBST is used for washing the plate for 2 times.
Furthermore, the invention also provides myoglobin pairing monoclonal antibody obtained by screening according to any one of the methods, wherein preferably, the pairing monoclonal antibody is secreted and produced by two hybridoma cells, namely MYO 3F1 and MYO 5A 8;
wherein, the hybridoma cell strain MYO 3F1 is preserved in the China general microbiological culture Collection center of China Committee for culture Collection of microorganisms with the preservation number of CGMCC No.18184 and the preservation time of 2019, 7 months and 5 days;
wherein, the hybridoma cell strain MYO 5A8 is preserved in China general microbiological culture Collection center (CGMCC) with the preservation number of CGMCC No.18185 and the preservation time of 2019, 7 months and 5 days.
Furthermore, the invention also provides the application of the myoglobin pairing monoclonal antibody in preparing a reagent for detecting the myoglobin antigen, wherein preferably, the reagent is suitable for an ELISA double-antibody sandwich method.
Compared with the prior art, the invention has the beneficial effects that:
1. because the coating antibody and the enzyme-labeled secondary antibody are essentially IgG from the same genus, the goat anti-MYO purified IgG pre-coating plate is adopted, so that the MYO antigen can be captured, indirect coating is completed, and the normal use of goat anti-mouse IgG-HRP (enzyme-labeled secondary antibody) is not influenced;
2. the indirect coating method of antibody pre-coating changes the preference of exposing the antigen epitope by the conventional coating method, obtains monoclonal antibody cell strains aiming at different MYO epitopes, improves the pairing screening probability, and finally successfully obtains paired cell strains.
Drawings
FIG. 1A is a schematic representation of MYO antigen;
FIG. 1B is a conventional screening method: direct coating of MYO antigen, and the subsequent steps are performed according to indirect ELISA: 1) Adding the supernatant; 2) enzyme-labeled secondary antibody; 3) developing color;
FIG. 1C shows a screening method of the present invention: coating goat anti-MYO purified IgG, adding MYO antigen, and performing indirect ELISA operation according to the following steps: 1) adding the supernatant; 2) enzyme-labeled secondary antibody; 3) and (4) developing color.
FIG. 1D is a schematic diagram of MYO mab pairing;
FIG. 2 shows the result of the pairing of mAb MYO-3F1 with MYO-5A 8.
Strain preservation information:
the myoglobin monoclonal antibody hybridoma cell strain is named as MYO 3F1 and classified and named as myoglobin monoclonal antibody hybridoma cell strain, is preserved in China General Microbiological Culture Collection Center (CGMCC), is addressed to the institute of microbiology, China academy of sciences, No. 3, China academy of sciences, North China, south China, Yangtze, China, West Asian province, No.1, the China, the preservation number is CGMCC No.18184, and the preservation time is 7 months and 5 days in 2019.
The myoglobin monoclonal antibody hybridoma cell strain is named as MYO 5A8 and classified and named as myoglobin monoclonal antibody hybridoma cell strain, and is preserved in China General Microbiological Culture Collection Center (CGMCC), the address of the microorganism research institute of China academy of sciences No. 3 of Ministry of China, West Lu 1 of the south China, the City, the preservation number is CGMCC No.18185, and the preservation time is 7 months and 5 days in 2019.
Detailed Description
The invention will be further described with reference to specific embodiments, and the advantages and features of the invention will become apparent as the description proceeds. These examples are illustrative only and do not limit the scope of the present invention in any way. It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention, and that such changes and modifications may be made without departing from the spirit and scope of the invention.
Example 1
1. Preparing materials: 1) myoglobin antigen was purchased from beijing lidman bio-chemical ltd; 2) goat anti-MYO purified IgG was purchased from Beijing Lidmann Biochemical Co., Ltd; 3) goat anti-mouse IgG-HRP was purchased from Beijing Lidmann Biochemical Co., Ltd; 4) Balb/C mice were purchased from Beijing Huafukang; 5) CB buffer solution: 50mM Na2CO3-NaHCO3A buffer (pH 9.6); 6) PBST: 150mM PBS (pH7.4, containing 0.05% Tween 20).
2. The experimental process comprises the following steps:
2.1 mouse immunization: mice were immunized as in table 1 below, and myoglobin antigen was emulsified with adjuvant and injected subcutaneously at multiple points in the back and abdomen.
TABLE 1
Number of immunizations Time interval (sky) Immunologic adjuvant Dosage of antigen
1 0 FCA 25ug
2 21 FIA 25ug
3 14 FIA 25ug
4 14 FIA 25ug
5 14 FIA 25ug
2.2 cell fusion:
performing impact immunization by intraperitoneal injection of myoglobin antigen without adjuvant 3 days before fusion, performing aseptic separation on the immune spleen on the day of fusion, preparing B cell suspension, mixing with SP2/0 cell, centrifuging, performing cell fusion by PEG1450, and culturing by DMEM medium containing 2% HAT and 10% fetal calf serum. Changing the culture medium on the 4 th day after fusion, gently sucking out the original culture medium, changing the original culture medium into a DMEM culture medium containing 1% HT and 10% fetal calf serum for culture, and detecting on the 6 th-12 th day.
2.3 fusion plate screening
2.3.1 methods of the invention
1) Enzyme label plate coating: goat anti-MYO purified IgG 50mM Na2CO3-NaHCO3Diluting buffer solution (pH9.6) to 5ug/ml, 100 ul/well, coating overnight at 2-8 deg.C, and washing plate with PBST for 1 time;
2) loading MYO antigen: MYO antigen is diluted to 1ug/ml with PBST, 100 ul/well, incubated at 37 ℃ for 30min, and washed with PBST for 1 time;
3) adding a sample on the fused plate: aseptically sampling hybridoma cell culture supernatant in an ultra-clean bench, incubating at 37 ℃ for 30min at 100 ul/hole, and washing the plate for 1 time by PBST;
4) goat anti-mouse IgG-HRP: using PBST to dilute goat anti-mouse IgG-HRP (enzyme-labeled secondary antibody) to a working concentration, 100 ul/hole, incubating for 30min at 37 ℃, and washing the plate for 2 times by using PBST;
5) developing and reading the plate: h2O2A TMB substrate, 100 ul/hole, color development in the dark at 37 ℃ for 5-10min, 2M H2SO4The color development is stopped at 50 ul/hole, and the plate is placed in an enzyme-linked immunosorbent assay and read at 450nm/630nm double-wavelength.
2.3.2 conventional methods
1) Enzyme label plate coating: 50mM Na for MYO antigen2CO3-NaHCO3Diluting buffer solution (pH9.6) to 5ug/ml, 100 ul/well, coating overnight at 2-8 deg.C, and washing plate with PBST for 1 time;
2) adding a sample on the fused plate: aseptically sampling hybridoma cell culture supernatant in an ultra-clean bench, incubating at 37 ℃ for 30min at 100 ul/hole, and washing the plate for 1 time by PBST;
3) goat anti-mouse IgG-HRP: using PBST to dilute goat anti-mouse IgG-HRP (enzyme-labeled secondary antibody) to a working concentration, 100 ul/hole, incubating for 30min at 37 ℃, and washing the plate for 2 times by using PBST;
4) developing and reading the plate: h2O2A TMB substrate, 100 ul/hole, color development in the dark at 37 ℃ for 5-10min, 2M H2SO4The color development is stopped at 50 ul/hole, and the plate is placed in an enzyme-linked immunosorbent assay and read at 450nm/630nm double-wavelength.
2.4 preparation of hybridoma and monoclonal antibody
Cloning the screened positive cells by a limiting dilution method, generally cloning for 2-3 times to obtain a monoclonal positive hybridoma cell strain, then carrying out amplification culture, and carrying out cryopreservation and ascites preparation on the cells. Purifying the ascites monoclonal antibody by a Protein G affinity purification method. The monoclonal antibody is labeled by Horse Radish Peroxidase (HRP) by using a modified sodium periodate method.
2.5 enzyme-labeled monoclonal antibody working concentration determination
1) Coating with MYO antigen: diluting MYO antigen with CB buffer solution to 1ug/ml, coating at 2-8 deg.C overnight, and washing plate with PBST for 1 time;
2) monoclonal antibody-HRP loading: diluting monoclonal antibody-HRP (enzyme labeled monoclonal antibody) with PBST to working concentration, 100 ul/hole, incubating at 37 ℃ for 30min, and washing the plate for 2 times with PBST;
3) developing and reading the plate: h2O2A TMB substrate, 100 ul/hole, color development in the dark at 37 ℃ for 5-10min, 2M H2SO4The color development is stopped at 50 ul/hole, and the plate is placed in an enzyme-linked immunosorbent assay and read at 450nm/630nm double-wavelength. And selecting the highest dilution multiple of the monoclonal antibody-HRP as the working concentration when the OD value is about 1.5.
2.6 monoclonal antibody pairing experiments
1) Coating with purified monoclonal antibody: purifying ascites monoclonal antibody of hybridoma cell secreting myoglobin monoclonal antibody, purifying monoclonal antibody with 50mM Na2CO3-NaHCO3Diluting buffer solution (pH9.6) to 5ug/ml, 100 ul/well, coating overnight at 2-8 deg.C, and washing plate with PBST for 1 time;
2) loading MYO antigen: MYO antigen is diluted to 1ug/ml with PBST, 100 ul/well, incubated at 37 ℃ for 30min, and washed with PBST for 1 time;
3) monoclonal antibody-HRP loading: diluting HRP enzyme-labeled monoclonal antibody matched with the coated monoclonal antibody to working concentration by PBST, incubating for 30min at 37 ℃ in 100 ul/hole, and washing the plate for 2 times by PBST;
4) developing and reading the plate: h2O2A TMB substrate, 100 ul/hole, color development in the dark at 37 ℃ for 5-10min, 2M H2SO4The coloration is stopped at 50 ul/hole, the plate is placed in an enzyme-linked immunosorbent assay, and the plate is read by 450nm/630nm double-wavelength, and the pairing is considered to be carried out when the wavelength is more than or equal to 1.0.
2.7 monoclonal antibody pairing results
46 hybridoma cells are obtained by the traditional method, but can not be matched; the method of the invention is adopted to obtain 6 strains of hybridoma cells, wherein 2 pairs can be selected: 3F1-5A 8; 4D6-5A8, with 3F1-5A8 being the best combination (Table 2), with 3F1 having a binding affinity constant (M)-1) Is 5.28X 109Binding affinity constant (M) for 4D6-1) Is 7.9 multiplied by 109Binding affinity constant (M) of 5A8-1) Is 5.21X 109。
The hybridoma cell strain 3F1 obtained by screening is named as MYO 3F1, and is classified and named as myoglobin monoclonal antibody hybridoma cell strain, the hybridoma cell strain is preserved in China General Microbiological Culture Collection Center (CGMCC), the address is in the institute of microbiology of China academy of sciences No. 3 of the West Lu 1 of the sunward district in Beijing, the preservation number is CGMCC No.18184, and the preservation time is 7 months and 5 days in 2019.
The hybridoma cell strain 5A8 obtained by screening is named as MYO 5A8, and is classified and named as myoglobin monoclonal antibody hybridoma cell strain, the hybridoma cell strain is preserved in China General Microbiological Culture Collection Center (CGMCC), the address is in the institute of microbiology of China academy of sciences No. 3 of Ministry of sciences, Ministry of China, North China, and south China, the south China Center of China Committee for Culture Collection (GmGmGmC) of south China, the China province, the China institute of sciences, the China, and the China, the Japan Collection method, the China, the south China.
TABLE 2 monoclonal antibody screening results

Claims (10)

1. A method for preparing a myoglobin pairing monoclonal antibody is characterized by comprising the following steps: comprises the steps of preparing hybridoma cells secreting anti-myoglobin monoclonal antibodies and screening paired monoclonal antibodies; when the hybridoma secreting the anti-myoglobin monoclonal antibody is screened by using an indirect ELISA method, a goat anti-MYO purified IgG coats an enzyme label plate, then a MYO antigen is added, then hybridoma cell culture supernatant and goat anti-mouse IgG-HRP are sequentially added, a color development reading plate is performed to obtain the hybridoma secreting the anti-myoglobin monoclonal antibody, and then monoclonal antibodies capable of being paired are screened from the hybridoma.
2. The method of claim 1, wherein: the preparation of hybridoma cells secreting anti-myoglobin monoclonal antibodies was carried out according to the following steps:
1) cell fusion: separating spleen of mouse with immune myoglobin antigen, preparing B cell suspension, mixing with SP2/0 cell, centrifuging, and performing cell fusion culture;
2) enzyme label plate coating: na for goat anti-MYO purified IgG2CO3-NaHCO3Diluting the buffer solution, adding the diluted buffer solution into an enzyme label plate, coating the enzyme label plate at 2-8 ℃ overnight, and washing the plate for 1 time by PBST;
3) adding MYO antigen: adding MYO antigen into the ELISA plate after PBST, incubating at 37 ℃, and washing the plate for 1 time by PBST;
4) adding hybridoma cell culture supernatant: aseptically sampling the fusion cell culture supernatant, adding the fusion cell culture supernatant into an enzyme label plate, incubating at 37 ℃, and washing the plate for 1 time by PBST;
5) addition of goat anti-mouse IgG-HRP: diluting goat anti-mouse IgG-HRP to working concentration with PBST, incubating at 37 ℃, and washing the plate for 2 times with PBST;
6) developing and reading the plate: addition of H2O2Developing the substrate with-TMB at 37 ℃ in the absence of light, adding 2M H2SO4And (3) stopping color development, placing the mixture in an enzyme labeling instrument, and reading a plate at 450nm/630nm double-wavelength to obtain the hybridoma secreting the anti-myoglobin monoclonal antibody.
3. The method of claim 2, wherein: spleen of immunized myoglobin antigen mouse is separated, B cell suspension is prepared, mixed with SP2/0 cell and centrifuged, and PEG is used1450Cell fusion was performed, and culture was performed in DMEM medium containing 2% v/v HAT and 10% v/v fetal bovine serum, and on day 4 after fusion, the medium was changed, and the medium was gently aspirated, and changed to DMEM medium containing 1% v/v HT and 10% v/v fetal bovine serum.
4. The method of claim 2, wherein: step 2) goat anti-MYO purified IgG 50mM Na2CO3-NaHCO3Buffer (pH9.6) diluted to 5ug/ml, 100 ul/well, 2-8 ℃ overnight coating, PBST washing plate 1Secondly; in step 3), the MYO antigen is diluted to 1ug/ml and 100 ul/well by PBST, incubated at 37 ℃ for 30min, and washed by PBST for 1 time.
5. The method of claim 2, wherein: in step 5) the goat anti-mouse IgG-HRP was diluted with PBST to working concentration, 100 ul/well, incubated at 37 ℃ for 30min, and washed 2 times with PBST.
6. The method of claim 1 or 2, wherein: the screening of the paired monoclonal antibodies is carried out according to the following steps:
1) coating with purified monoclonal antibody: purifying an ascites monoclonal antibody of a hybridoma cell secreting the anti-myoglobin monoclonal antibody, diluting the purified monoclonal antibody, adding the diluted purified monoclonal antibody into a new enzyme label plate, coating overnight, and washing the plate for 1 time by PBST;
2) loading MYO antigen: adding MYO antigen into the ELISA plate after PBST, incubating at 37 ℃, and washing the plate for 1 time by PBST;
3) loading HRP enzyme-labeled monoclonal antibody: diluting the HRP enzyme-labeled monoclonal antibody matched with the coated monoclonal antibody by PBST, adding the diluted HRP enzyme-labeled monoclonal antibody into an enzyme-labeled plate, incubating at 37 ℃, and washing the plate for 2 times by PBST;
4) developing and reading the plate: addition of H2O2Developing the substrate with-TMB at 37 ℃ in the absence of light, adding 2M H2SO4And (3) stopping color development, placing the sample in an enzyme-labeling instrument, reading a plate with 450nm/630nm double-wavelength, and determining that the sample can be matched if the wavelength of 450nm/630nm is more than or equal to 1.0.
7. The method of claim 6, wherein: 50mM Na is used for purifying the monoclonal antibody in the step 1)2CO3-NaHCO3Buffer (pH9.6) diluted to 5ug/ml, 100 ul/hole, 2-8 ℃ overnight coating, PBST washing plate 1 times.
8. The method of claim 6, wherein: diluting MYO antigen with PBST in step 2) to 1ug/ml and 100 ul/well, incubating at 37 deg.C for 30min, and washing plate with PBST for 1 time; in the step 3), the HRP enzyme-labeled monoclonal antibody matched with the coated monoclonal antibody is diluted to the working concentration by PBST, 100 ul/hole is incubated for 30min at 37 ℃, and the PBST is used for washing the plate for 2 times.
9. Myoglobin paired monoclonal antibody screened according to the method of any one of claims 1-8, wherein preferably, the paired monoclonal antibody is secreted by two hybridoma cells, i.e., MYO 3F1 and MYO 5A 8;
wherein, the hybridoma cell strain MYO 3F1 is preserved in the China general microbiological culture Collection center of China Committee for culture Collection of microorganisms with the preservation number of CGMCC No.18184 and the preservation time of 2019, 7 months and 5 days;
wherein, the hybridoma cell strain MYO 5A8 is preserved in China general microbiological culture Collection center (CGMCC) with the preservation number of CGMCC No.18185 and the preservation time of 2019, 7 months and 5 days.
10. Use of the myoglobin pairing mab of claim 9 in the preparation of a reagent for detecting myoglobin antigen, wherein preferably said reagent is suitable for ELISA double antibody sandwich assay.
CN201910881837.4A 2019-09-18 2019-09-18 Method for preparing myoglobin pairing monoclonal antibody and pairing monoclonal antibody prepared by method Pending CN110590949A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910881837.4A CN110590949A (en) 2019-09-18 2019-09-18 Method for preparing myoglobin pairing monoclonal antibody and pairing monoclonal antibody prepared by method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910881837.4A CN110590949A (en) 2019-09-18 2019-09-18 Method for preparing myoglobin pairing monoclonal antibody and pairing monoclonal antibody prepared by method

Publications (1)

Publication Number Publication Date
CN110590949A true CN110590949A (en) 2019-12-20

Family

ID=68860763

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910881837.4A Pending CN110590949A (en) 2019-09-18 2019-09-18 Method for preparing myoglobin pairing monoclonal antibody and pairing monoclonal antibody prepared by method

Country Status (1)

Country Link
CN (1) CN110590949A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112521497A (en) * 2020-12-17 2021-03-19 杭州贤至生物科技有限公司 Preparation and application of myoglobin monoclonal antibody
CN113929777A (en) * 2020-07-13 2022-01-14 东莞市朋志生物科技有限公司 Anti-myoglobin antibody, kit and method for detecting myoglobin

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996010077A1 (en) * 1994-09-28 1996-04-04 Spectral Diagnostics Inc. Monoclonal antibody to human cardiac myoglobin
CN106443018A (en) * 2016-08-31 2017-02-22 上海科华生物工程股份有限公司 Myoglobin monoclonal abzyme marking compound and preparation method thereof and detection test kit

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996010077A1 (en) * 1994-09-28 1996-04-04 Spectral Diagnostics Inc. Monoclonal antibody to human cardiac myoglobin
CN106443018A (en) * 2016-08-31 2017-02-22 上海科华生物工程股份有限公司 Myoglobin monoclonal abzyme marking compound and preparation method thereof and detection test kit

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
杨超一等: "抗肌红蛋白单克隆抗体的制备与鉴定及其初步应用", 《LABELED IMMUNOASSAYS ＆ CLIN MED》 *
王梦玖等: "《临床生殖免疫学》", 31 December 2000, 上海科学技术出版社 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113929777A (en) * 2020-07-13 2022-01-14 东莞市朋志生物科技有限公司 Anti-myoglobin antibody, kit and method for detecting myoglobin
CN112521497A (en) * 2020-12-17 2021-03-19 杭州贤至生物科技有限公司 Preparation and application of myoglobin monoclonal antibody
CN112521497B (en) * 2020-12-17 2022-05-20 杭州贤至生物科技有限公司 Preparation and application of myoglobin monoclonal antibody

Similar Documents

Publication Publication Date Title
US20090280507A1 (en) Method for measurement of sars virus nucleocapsid protein, reagent kit for the measurement, test device, monoclonal antibody directed against sars virus nucleocapsid protein, and hybridoma capable of producing the monoclonal antibody
CN112679605B (en) Antibodies or antigen binding fragments thereof against novel coronavirus nucleocapsid proteins and uses thereof
Hokama Simplified solid‐phase immunobead assay for detection of ciguatoxin and related polyethers
US8546093B2 (en) Detection method for methicillin resistant staphylococcus aureus
WO2018133039A1 (en) Method and kit for preparing antibody pair and use of kit, and system for preparing antibody pair
CN110590949A (en) Method for preparing myoglobin pairing monoclonal antibody and pairing monoclonal antibody prepared by method
CN108912090B (en) Test strip for rapidly detecting total amount of alternariol and alternariol monomethyl ether
CN107271685A (en) A kind of method and its dedicated kit for detecting the content of fowl leukocyte interleukin 2
CN101759797A (en) Phycocyanin beta subunits fluorescent protein combined with phycoerythrobilin PEB and application thereof
WO2023036152A1 (en) Detection method and kit for sars-cov-2
CN113150133B (en) Monoclonal antibodies against SARS-CoV-2 or antigen binding fragments thereof
CN112175072B (en) Monoclonal antibody ZJU5-01 for resisting H5 subtype avian influenza virus hemagglutinin protein and application thereof
CN112986586A (en) Amino-terminal brain natriuretic peptide detection method and kit
CN108359642B (en) Hybridoma cell of shrimp tropomyosin monoclonal antibody and application thereof
WO2016074626A1 (en) Antibody elisa kit of anti-hepatitis b virus x protein and preparation method thereof
EP3531129B1 (en) Immunoassay method using anti-human bnp fragment (4-32) antibody
EP1347301A1 (en) Method for ultra-rapid and ultra-sensitive measurement
CN112964885B (en) Amino-terminal brain natriuretic peptide detection method and kit
CN101759786A (en) Phycocyanin alpha subunits fluorescent protein combined with phycocyanobilin PCB and application thereof
CN106929477B (en) Anti-prostaglandin F2αSpecific monoclonal antibody hybridoma cell strain WXX-2 and application thereof
JPH04502363A (en) Detection of basement membrane components for diagnosis of cancer and other diseases
WO2019129082A1 (en) A lincosamide universal monoclonal antibody hybridoma cell strain and application thereof
CN113185530B (en) Hybridoma cell strain, 2-type euglena brevibacterium toxin monoclonal antibody secreted by hybridoma cell strain and application of monoclonal antibody
CN114910643B (en) Method and reagent for identifying antibody combined with mutant antigen
CN115627264B (en) anti-Malneffei mannan protein hybridoma cell strain and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20191220

RJ01 Rejection of invention patent application after publication